Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection
Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34440
- Istanbul Bilgi University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between the ages of 28-45, positive COVID-19 test, being in the post-acute period, having symptoms of mild-moderate severity, respiratory rate ≤40 breaths / min, patients who can make video speech
Exclusion Criteria:
- Severe symptom involvement, fever more than 38 degrees, obese patients, patients with multiple comorbidities, patients with one or more organ failure, oxygen saturation in the blood ≤95%, a resting blood pressure of <90/60 mmHg or> 140 / 90 mmHg patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pulmonary Rehabilitation
The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day.
Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
|
Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
|
|
Placebo Comparator: Control
As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
|
Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dyspnea
Time Frame: Baseline, up to 4 weeks
|
The Borg scale is a scale scored between 0-10, indicating the severity of dyspnea.
0 indicates no shortness of breath, 10 indicates severe shortness of breath
|
Baseline, up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chest expansion
Time Frame: Baseline, up to 4 weeks
|
Chest expansion was evaluated by measuring the difference between the maximum inspiration and maximum expiration from the level of xsphoid processus of the patients.
|
Baseline, up to 4 weeks
|
|
Fatigue severity
Time Frame: Baseline, up to 4 weeks
|
Fatigue severity scale is a questionnaire consisting of 9 questions showing the degree of fatigue of patients.
An average score of less than 2.8 indicates no fatigue, and more than 6.1 indicates chronic fatigue syndrome
|
Baseline, up to 4 weeks
|
|
Visual Analog Scale for pain
Time Frame: Baseline, up to 4 weeks
|
Patients were instructed and asked to give a score between 0-10 with 0 equating to no pain, 10 indicating severe pain
|
Baseline, up to 4 weeks
|
|
Hospital anxiety and depression scale
Time Frame: Baseline, up to 4 weeks
|
The HAD scale is a short self administered questionnaire used to screen for anxiety and depression.
The questionnaire consists of 14 items, seven each measuring anxiety and seven to measure depression.
According to research literature, the cut-off point for elevated anxiety and depression as measured by the HAD scale is eight
|
Baseline, up to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PR COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.